{"id":"W4210332821","doi":"10.1016/s1470-2045(21)00757-9","title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"Janssen Biotech; Daiichi Sankyo Europe; National Cancer Institute; Pharmacyclics; Stand Up To Cancer; Janssen Research and Development; EMD Serono; Genentech; Ipsen; Astellas Pharma; Daiichi-Sankyo; Seagen; Pfizer; Incyte; National Institutes of Health; Menarini Silicon Biosystems; Eli Lilly and Company; U.S. Department of Defense; Sanofi; Exelixis; Flatiron Health; Advanced Accelerator Applications; Endocyte; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; American Association for Cancer Research; Amgen","keywords":"Prostate cancer; DNA repair; Gene; DNA; DNA Damage Repair; Phase (matter); Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008123791,0.000176285,0.0006278191,0.00008240715,0.000222551,0.00002455009,0.0001795297,0.00003482892,0.0002416336],"category_scores_gemma":[0.00005594602,0.0001228693,0.00002625266,0.0003325068,0.0001532021,0.00009975184,0.0001269435,0.0003646878,0.000002970489],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006083083,"about_ca_system_score_gemma":0.0006316818,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000339128,"about_ca_topic_score_gemma":0.0009179139,"domain_scores_codex":[0.9979945,0.0005488576,0.0003888587,0.000369797,0.0003146037,0.0003834087],"domain_scores_gemma":[0.9989833,0.0002091493,0.0002685485,0.0003618031,0.00008542295,0.00009181682],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9305204,0.008661733,0.02490583,0.0001676834,0.0006718786,0.0004481533,0.005877036,0.0002640088,0.01135768,0.0004992569,0.009280877,0.007345438],"study_design_scores_gemma":[0.9087397,0.02056072,0.01867496,0.00008319216,0.0003858053,0.00004952548,0.000554871,0.0004709699,0.0009621949,0.0002250297,0.04898044,0.0003125602],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916382,0.0005547708,0.000004282063,0.00286471,0.0002885885,0.003900501,0.000255927,0.00005012623,0.0004429027],"genre_scores_gemma":[0.9922467,0.0001430164,0.001297604,0.003247322,0.0001769315,0.002471876,0.0001249266,0.00003209997,0.0002595535],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03969957,"threshold_uncertainty_score":0.5010465,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08052415143704984,"score_gpt":0.3979720798969069,"score_spread":0.317447928459857,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}